Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Real-world experience with IDH inhibitors in Acute Myeloid Leukemia: A german multicenter analysis with a focus on differentiation syndrome

Krischan Braitsch, Karin Huber, Andrew Berdel, Lydia Kretschmer, Adrian Gottschlich, Tim Lohmann, Kathrin Rieger, Karsten Spiekermann, Thomas Schroeder, Silke Kapp-Schwoerer, Mareike Verbeek, Florian Bassermann, Hartmut Döhner, Tim Sauer, Christoph Röllig, Jan-Henrik Mikesch, Franziska Westendorf, Lars Fransecky, Katharina S. Götze

Blood (2025) 146 (Supplement 1): 2846.

https://doi.org/10.1182/blood-2025-2846

Published: 2025

Journal Articles

Venetoclax combined with five days of azacitidine for the treatment of previously untreated Acute Myeloid Leukemia (AML): Initial results of the prospective venaza-5S trial

Klaus Metzeler, Jens Przybilla, Anne Weigert, Mathias Hänel, Thomas Illmer, Julia Pross, Alexander Höllein, Martin Schmidt-Hieber, Ullrich Graeven, Tim Sauer, Stefan Neuburger, Katharina S. Götze, Dominic Brauer, Madlen Jentzsch, Christoph Röllig, Dirk Hasenclever, Uwe Platzbecker

Blood (2025) 146 (Supplement 1): 46.

https://doi.org/10.1182/blood-2025-46

Published: 2025

Journal Articles

Prospective clinical validation of MAC-scoring as an affordable, real-time biomarker for HMA/venetoclax response in AML

Simon Renders, Alexander Waclawiczek, Ricarda Schwab, Julia Unglaub, Aino-Maija Leppä, Stefan Klein, Tim Sauer, Carsten Müller-Tidow, Michael Hundemer, Andreas Trumpp

Blood (2025) 146 (Supplement 1): 3493.

https://doi.org/10.1182/blood-2025-3493

Published: 2025

Journal Articles

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Blood (2025) 146 (Supplement 1): 5230.

https://doi.org/10.1182/blood-2025-5230

Published: 2025

Journal Articles

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Jenny O'Nions, Andrew Wei, Jordi Esteve, Ibrahim Aldoss, Ana Alfonso-Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Nikki Daskalakis, Matteo Della Porta, Hartmut Döhner, Amber D'Souza, James Dugan, Amir Fathi, Pasquale Fedele, Lucille Ferrante, Rachel Kobos, Ana Garrido, Sara Garrido Paniagua, Christina Drenberg Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Danielle Trancucci, Naa Sackey, Madlen Jentzsch, Hagop Kantarjian, Marina Konopleva, Jan Krönke, Marie Luise Hütter-Krönke, Christina Loefgren, Oliver Lomas, Valentina Mancini, Daniel Morillo, Kathryn Packman, Cristina Papayannidis, Christian Recher, Christoph Röllig, Olga Salamero, Prathap Nagaraja Shastri, Tim Sauer, Dr. Emma Searle, Natalia Tovar, Nicolas Vallet, Lachlin Vaughan, Paresh Vyas, Uwe Platzbecker, Sylvain Garciaz

Blood (2025) 146 (Supplement 1): 5200.

https://doi.org/10.1182/blood-2025-5200

Published: 2025

Journal Articles

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Hartmut Döhner, Andre Schuh, Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso-Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Nikki Daskalakis, Matteo Della Porta, Amber D'Souza, James Dugan, Jordi Esteve, Amir Fathi, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Olga Salamero, Christina Drenberg Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop Kantarjian, Marina Konopleva, Jan Krönke, Marie Luise Hütter-Krönke, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Daniel Morillo, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sara Garrido Paniagua, Naa Sackey, Tim Sauer, Dr. Emma Searle, Prathap Nagaraja Shastri, Danielle Trancucci, Natalia Tovar, Nicolas Vallet, Lachlin Vaughan, Paresh Vyas, Andrew Wei, Christoph Röllig

Blood (2025) 146 (Supplement 1): 5199.

https://doi.org/10.1182/blood-2025-5199

Published: 2025

Journal Articles

Single versus double “7+3” induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD?

Blood (2025) 146 (Supplement 1): 5298.

https://doi.org/10.1182/blood-2025-5298

Published: 2025

Journal Articles

A Venetoclax/Azacytidine Single-Cell RNA-Seq Resistance Signature (VARS) Predicts Response and Relapse in AML Patients

Anne Kathrin Merbach, Christian Rohde, Sergi Beneyto-Calabuig, Patrick Stelmach, Aino-Maija Leppä, Alexander Waclawiczek, Simon Renders, Michelle Lotze, Lars Velten, Andreas Trumpp, Tim Sauer, Rabia Shahswar, Michael Heuser, Carsten Müller-Tidow, Maike Janssen

Blood (2024) 144 (Supplement 1): 5744.

https://doi.org/10.1182/blood-2024-209706

Published: 2024

Journal Articles

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Martin Curtis, Nikki Daskalakis, Matteo Giovanni Della Porta, Hartmut Döhner, Amber D'Souza, James P. Dugan, Jordi Esteve Reyner, Matthew Exum, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Sara Garrido Paniagua, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop M. Kantarjian, Marina Konopleva, Jan Krönke, Min Chul Kwon, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Giovanni Martinelli, Daniel Morillo Giles, Joseph Murphy, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sravanti Rangaraju, Christoph Röllig, Olga Salamero, Madhu Sanga, Tim Sauer, Emma Searle, Natalia Tovar, Trevor Tucker, Nicolas Vallet, Lachlin Vaughan, Gala Vega, Paresh Vyas, Andrew Wei

Blood (2024) 144 (Supplement 1): 215.

https://doi.org/10.1182/blood-2024-207072

Published: 2024

Journal Articles

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1 -Mutated AML - the SAL/AMLCG Vincent Trial

Blood (2024) 144 (Supplement 1): 1527.1.

https://doi.org/10.1182/blood-2024-198164

Published: 2024

Journal Articles

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Jan-Niklas Eckardt, Marius Bill, Konstanze Döhner, Christian Rausch, Klaus H Metzeler, Karsten Spiekermann, Sebastian Stasik, Tim Sauer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. H. Brummendorf, Utz Krug, Bernhard Wörmann, Hermann Einsele, Wolfgang Hiddemann, Dennis Görlich, Maria Cristina Sauerland, Björn Steffen, Andreas Neubauer, Andreas Burchert, Kerstin Schaefer-Eckart, Wolfgang E. Berdel, Christoph Schliemann, Stefan W. Krause, Mathias Hänel, Maher Hanoun, Martin Kaufmann, Lars Fransecky, Jan Braess, Johannes Schetelig, Jan Moritz Middeke, Lars Bullinger, Michael Heuser, Felicitas R Thol, Hubert Serve, Claudia D Baldus, Uwe Platzbecker, Carsten Mueller-Tidow, Barbora Weinbergerova, Jiri Mayer, Pierre-Yves Dumas, Sarah Bertoli, Eric Delabesse, Christian Récher, Arnaud Pigneux, Tobias Herold, Arnold Ganser, Hartmut Döhner, Martin Bornhäuser, Christian Thiede, Christoph Röllig

Blood (2024) 144 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2024-201945

Published: 2024

Journal Articles

A First in Human Study of VOB560 in Combination with MIK665 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, or Multiple Myeloma

Blood (2024) 144 (Supplement 1): 5997.

https://doi.org/10.1182/blood-2024-199074

Published: 2024

Journal Articles

Structurally Optimized, IL-2-Armored CLL1 CAR-NK Cells Are Highly Potent Effectors Against AML without Hpsc Toxicity

David N. Sedloev, Qian Chen, Julia M. Unglaub, Anita Schmitt, Carsten Müller-Tidow, Michael Schmitt, Tim Sauer

Blood (2024) 144 (Supplement 1): 3440.

https://doi.org/10.1182/blood-2024-210286

Published: 2024

Journal Articles

Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis

Blood (2024) 144 (Supplement 1): 3818.

https://doi.org/10.1182/blood-2024-211227

Published: 2024

Journal Articles

The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature

Anna Mathioudaki, Xizhe Wang, David Sedloev, Richard Huth, Aryan Kamal, Michael Hundemer, Yi Liu, Spyridoula Vasileiou, Premal Lulla, Carsten Müller-Tidow, Peter Dreger, Thomas Luft, Tim Sauer, Michael Schmitt, Judith B. Zaugg, Caroline Pabst

Blood (2024) 143 (13): 1269–1281.

https://doi.org/10.1182/blood.2023021815

Published: 2024

Includes: Supplemental data

Journal Articles

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial

Blood (2023) 142 (Supplement 1): 5907.

https://doi.org/10.1182/blood-2023-179168

Published: 2023

Journal Articles

Venetoclax and Blinatumomab for Adult Patients with Relapsed/Refractory or MRD Positive Ph-Negative B-Precursor ALL: First Results of the GMALL-Bliven Trial

Lars Fransecky, Walter Fiedler, Christoph Röllig, Tim Sauer, Simon Raffel, Winfried Alsdorf, Lisa Heberling, Kumaran Nagarajan, Britta Steer, Philipp Nakov, Björn Steffen, Dorothee Deckbar, Sonja Bendig, Lorenz Bastian, Martin Neumann, Monika Brueggemann, Nicola Goekbuget, Claudia D Baldus

Blood (2023) 142 (Supplement 1): 1502.

https://doi.org/10.1182/blood-2023-173937

Published: 2023

Journal Articles

Improving Anti-Tumor Efficacy of CAR T-Cell Therapy for Acute Myeloid Leukemia (AML): Results from a Multi-Drug Interaction Screening Approach

Julia M. Unglaub, Berit Brinkmann, Qian Chen, David Sedloev, Peter-Martin Bruch, Carolin Kolb, Volker Eckstein, Yi Liu, Anita Schmitt, Simon Raffel, Michael Schmitt, Carsten Müller-Tidow, Junyan Lu, Sascha Dietrich, Tim Sauer

Blood (2023) 142 (Supplement 1): 5969.

https://doi.org/10.1182/blood-2023-181251

Published: 2023

Journal Articles

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

Blood (2023) 142 (Supplement 1): 721.

https://doi.org/10.1182/blood-2023-186160

Published: 2023

Journal Articles

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Blood (2022) 140 (24): 2594–2610.

https://doi.org/10.1182/blood.2021014241

Published: 2022

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real-world experience with IDH inhibitors in Acute Myeloid Leukemia: A german multicenter analysis with a focus on differentiation syndrome

Venetoclax combined with five days of azacitidine for the treatment of previously untreated Acute Myeloid Leukemia (AML): Initial results of the prospective venaza-5S trial

Prospective clinical validation of MAC-scoring as an affordable, real-time biomarker for HMA/venetoclax response in AML

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Single versus double “7+3” induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD?

A Venetoclax/Azacytidine Single-Cell RNA-Seq Resistance Signature (VARS) Predicts Response and Relapse in AML Patients

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1 -Mutated AML - the SAL/AMLCG Vincent Trial

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

A First in Human Study of VOB560 in Combination with MIK665 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, or Multiple Myeloma

Structurally Optimized, IL-2-Armored CLL1 CAR-NK Cells Are Highly Potent Effectors Against AML without Hpsc Toxicity

Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis

The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial

Venetoclax and Blinatumomab for Adult Patients with Relapsed/Refractory or MRD Positive Ph-Negative B-Precursor ALL: First Results of the GMALL-Bliven Trial

Improving Anti-Tumor Efficacy of CAR T-Cell Therapy for Acute Myeloid Leukemia (AML): Results from a Multi-Drug Interaction Screening Approach

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only